Sermorelin

5.9

Worth trying, BioHarmony verdict

BioHarmony score 5.9 out of 10

Sermorelin (GHRH 1-29) is a short-acting peptide that prompts your own pituitary to release growth hormone, and it is the only one in its class with a former FDA approval and real human trials, per Thorner 1996. Adult anti-aging data is thin and mixed, with a null body-composition trial per Vittone 1997.

Read full report

What is Sermorelin?

Sermorelin is the synthetic 1-29 amino-acid fragment of growth-hormone-releasing hormone, the shortest piece of the natural signal that still tells your pituitary to fire off a pulse of growth hormone. Instead of injecting growth hormone directly, you nudge your own gland to release it the way it normally would, in a brief burst that rises and falls. That keeps your natural feedback brakes in place, which is the whole pitch for calling it more physiological than recombinant HGH.

From the BioHarmony report, reviewed Sep 8, 2026.

Saved on this device only.

How it is thought to work

Agonist at the pituitary GHRH receptor, amplifying the body's own pulsatile growth-hormone release

Safety watch-outs

  • Progressive or worsening reaction with each injection (possible sensitization): stop immediately.
  • New or worsening numbness or tingling (possible fluid-related nerve compression): reduce dose or stop.
  • Rising fasting glucose: stop and consult a clinician, especially with diabetes or insulin resistance.
  • Any active or suspected cancer: do not use
  • growth-hormone-axis stimulation is contraindicated.

Full risk profile in the BioHarmony report.

Dosing as published

Source-reported figures only. This page does not calculate a personal dose.

Approved labelDiscontinued GEREF pediatric prescribing information; FDA determined the product was not withdrawn for safety or effectiveness reasons
PopulationChildren covered by the former approved growth-hormone-deficiency indication
Dose0.03 mg/kg once daily at bedtime by subcutaneous injection
RouteSubcutaneous injection
FrequencyOnce daily at bedtime
DurationAs directed in the historical prescribing information with growth-response monitoring
PreparationThe historical 0.5 mg and 1 mg GEREF vials were reconstituted with 0.5-1 mL Sodium Chloride Injection, USP, immediately before use; the discontinued product label controls the formulation-specific method.
Source: Dosage and Administration; Preparation and How Supplied

Working with a vial? The reconstitution calculator covers mixing math, not dosing advice.

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Educator coverage (1)

Attributed viewpoints, separate from primary research.

Trust & sourcing

  1. Last revieweddone
  2. Next reviewupcoming
US approvalFDA-approved product exists
CompoundingHistorical approval does not make currently compounded sermorelin FDA approved

FDA records show that sermorelin acetate for injection was approved as Geref. The branded product is no longer marketed; compounded sermorelin products do not inherit the former product's approval.

Primary sources

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.